Literature DB >> 21859801

Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy.

Angeliki Asimaki1, Harikrishna Tandri, Elizabeth R Duffy, Jeffrey R Winterfield, Shannon Mackey-Bojack, Maria M Picken, Leslie T Cooper, David J Wilber, Frank I Marcus, Cristina Basso, Gaetano Thiene, Adalena Tsatsopoulou, Nikos Protonotarios, William G Stevenson, William J McKenna, Shiva Gautam, Daniel G Remick, Hugh Calkins, Jeffrey E Saffitz.   

Abstract

BACKGROUND: Immunoreactive signal for the desmosomal protein plakoglobin (γ-catenin) is reduced at cardiac intercalated disks in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), a highly arrhythmogenic condition caused by mutations in genes encoding desmosomal proteins. Previously, we observed a false-positive case in which plakoglobin signal was reduced in a patient initially believed to have ARVC but who actually had cardiac sarcoidosis. Sarcoidosis can masquerade clinically as ARVC but has not been previously associated with altered desmosomal proteins. METHODS AND
RESULTS: We observed marked reduction in immunoreactive signal for plakoglobin at cardiac myocyte junctions in patients with sarcoidosis and giant cell myocarditis, both highly arrhythmogenic forms of myocarditis associated with granulomatous inflammation. In contrast, plakoglobin signal was not depressed in lymphocytic (nongranulomatous) myocarditis. To determine whether cytokines might promote dislocation of plakoglobin from desmosomes, we incubated cultures of neonatal rat ventricular myocytes with selected inflammatory mediators. Brief exposure to low concentrations of interleukin (IL)-17, tumor necrosis factor-α (TNF-α), and IL-6 (cytokines implicated in granulomatous myocarditis) caused translocation of plakoglobin from cell-cell junctions to intracellular sites, whereas other potent cytokines implicated in nongranulomatous myocarditis had no effect, even at much higher concentrations. We also observed myocardial expression of IL-17 and TNF-α and elevated levels of serum inflammatory mediators, including IL-6R, IL-8, monocyte chemoattractant protein 1, and macrophage inflammatory protein 1β, in patients with ARVC (all P<0.0001 compared with controls).
CONCLUSIONS: The results suggest novel disease mechanisms involving desmosomal proteins in granulomatous myocarditis and implicate cytokines, perhaps derived in part from the myocardium, in disruption of desmosomal proteins and arrhythmogenesis in ARVC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859801      PMCID: PMC3203520          DOI: 10.1161/CIRCEP.111.964890

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  45 in total

1.  Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

Authors:  A Deswal; N J Petersen; A M Feldman; J B Young; B G White; D L Mann
Journal:  Circulation       Date:  2001-04-24       Impact factor: 29.690

2.  Levels of serum interleukin-10 reflect disease activity in patients with cardiac sarcoidosis.

Authors:  K Fuse; M Kodama; Y Okura; M Ito; Y Aoki; S Hirono; K Kato; H Hanawa; Y Aizawa
Journal:  Jpn Circ J       Date:  2000-10

3.  Giant cell myocarditis, in a patient with Crohn's disease, treated with etanercept--a tumour necrosis factor-alpha antagonist.

Authors:  C L Nash; R Panaccione; L R Sutherland; J B Meddings
Journal:  Can J Gastroenterol       Date:  2001-09       Impact factor: 3.522

4.  Cytokine mediated regulation of interferon-gamma-induced IDO activation.

Authors:  C R MacKenzie; R G González; E Kniep; S Roch; W Däubener
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

Review 5.  Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective.

Authors:  William S Bradham; Biykem Bozkurt; Himali Gunasinghe; Douglas Mann; Francis G Spinale
Journal:  Cardiovasc Res       Date:  2002-03       Impact factor: 10.787

Review 6.  Giant cell myocarditis: most fatal of autoimmune diseases.

Authors:  E D Rosenstein; M J Zucker; N Kramer
Journal:  Semin Arthritis Rheum       Date:  2000-08       Impact factor: 5.532

7.  Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure.

Authors:  H G Eiken; E Øie; J K Damås; A Yndestad; V Bjerkeli; H Aass; S Simonsen; O R Geiran; T Tønnessen; G Christensen; S S Frøland; L Gullestad; H Attramadal; P Aukrust
Journal:  Eur J Clin Invest       Date:  2001-05       Impact factor: 4.686

8.  Autocrine regulation of myocyte Cx43 expression by VEGF.

Authors:  Rhea C Pimentel; Kathryn A Yamada; André G Kléber; Jeffrey E Saffitz
Journal:  Circ Res       Date:  2002-04-05       Impact factor: 17.367

9.  Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.

Authors:  Edith K Podewski; Denise Hilfiker-Kleiner; Andres Hilfiker; Henning Morawietz; Artur Lichtenberg; Kai C Wollert; Helmut Drexler
Journal:  Circulation       Date:  2003-02-18       Impact factor: 29.690

10.  Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.

Authors:  Maria E Campian; Hein J Verberne; Maxim Hardziyenka; Elisabeth A A de Groot; Astrid F van Moerkerken; Berthe L F van Eck-Smit; Hanno L Tan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-06       Impact factor: 9.236

View more
  56 in total

1.  Plakoglobin: a diagnostic marker of arrhythmogenic right ventricular cardiomyopathy in forensic pathology?

Authors:  Julie Munkholm; Claus B Andersen; Gyda L Ottesen
Journal:  Forensic Sci Med Pathol       Date:  2015-01-01       Impact factor: 2.007

Review 2.  Molecular mechanisms in the pathogenesis of arrhythmogenic cardiomyopathy.

Authors:  Jeffrey E Saffitz
Journal:  Cardiovasc Pathol       Date:  2017-02-27       Impact factor: 2.185

3.  Arrhythmogenic right ventricular cardiomyopathy mutations alter shear response without changes in cell-cell adhesion.

Authors:  Venkatesh Hariharan; Angeliki Asimaki; Jarett E Michaelson; Eva Plovie; Calum A MacRae; Jeffrey E Saffitz; Hayden Huang
Journal:  Cardiovasc Res       Date:  2014-09-24       Impact factor: 10.787

4.  Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy.

Authors:  Stephen P Chelko; Angeliki Asimaki; Justin Lowenthal; Carlos Bueno-Beti; Djahida Bedja; Arianna Scalco; Nuria Amat-Alarcon; Peter Andersen; Daniel P Judge; Leslie Tung; Jeffrey E Saffitz
Journal:  Circulation       Date:  2019-09-19       Impact factor: 29.690

Review 5.  Small steps for idiopathic giant cell myocarditis.

Authors:  Jeffrey A Shih; Jennifer A Shih
Journal:  Curr Heart Fail Rep       Date:  2015-06

Review 6.  Gap junctions and arrhythmogenic cardiomyopathy.

Authors:  Angeliki Asimaki; Jeffrey E Saffitz
Journal:  Heart Rhythm       Date:  2011-11-16       Impact factor: 6.343

7.  Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy.

Authors:  Angeliki Asimaki; Sudhir Kapoor; Eva Plovie; Anne Karin Arndt; Edward Adams; ZhenZhen Liu; Cynthia A James; Daniel P Judge; Hugh Calkins; Jared Churko; Joseph C Wu; Calum A MacRae; André G Kléber; Jeffrey E Saffitz
Journal:  Sci Transl Med       Date:  2014-06-11       Impact factor: 17.956

8.  Giant cell myocarditis. Diagnosis and treatment.

Authors:  L T Cooper; C ElAmm
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

9.  Arrhythmogenic right ventricular dysplasia back in force.

Authors:  Guy Fontaine; Huei-Sheng Vincent Chen
Journal:  Am J Cardiol       Date:  2014-03-14       Impact factor: 2.778

Review 10.  Remodeling of cell-cell junctions in arrhythmogenic cardiomyopathy.

Authors:  Angeliki Asimaki; Jeffrey E Saffitz
Journal:  Cell Commun Adhes       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.